These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36682771)

  • 1. Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.
    Yanase T; Hatano M; Bujo C; Tsuji M; Ishida J; Amiya E; Okamoto K; Ando M; Shimada S; Kinoshita O; Fukushi S; Yamada S; Ono M; Komuro I
    Int Heart J; 2023 Mar; 64(1):95-99. PubMed ID: 36682771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).
    Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S
    Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
    Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
    Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients.
    Kim YJ; Boeckh M; Cook L; Stempel H; Jerome KR; Boucek R; Burroughs L; Englund JA
    Transpl Infect Dis; 2012 Dec; 14(6):611-7. PubMed ID: 23198963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir treatment for CMV infection in kidney and pancreas transplantation: A valuable option for complicated cases.
    Ortiz F; Lempinen M; Aaltonen S; Koivuviita N; Helanterä I
    Clin Transplant; 2022 Feb; 36(2):e14537. PubMed ID: 34797574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
    Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
    Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case Report of Successful Use of Twice-Daily Letermovir in the Treatment of Resistant Cytomegalovirus in a Small Bowel Transplant Recipient.
    Joharji H; Alaidaros F; Koujan H; Hamad A; Almaghrabi RS; Zidan A; Broering D; Al-Jedai A
    Transplant Proc; 2022; 54(6):1679-1681. PubMed ID: 35842318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis.
    Erice A; Borrell N; Li W; Miller WJ; Balfour HH
    J Infect Dis; 1998 Aug; 178(2):531-4. PubMed ID: 9697737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    Noble S; Faulds D
    Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients.
    Boignard A; Augier C; Kheng M; Epaulard O; Germi R
    Antivir Ther; 2022 Dec; 27(6):13596535221133619. PubMed ID: 36398571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
    Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
    Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay.
    Yang CW; Kim YO; Kim YS; Kim SY; Moon IS; Ahn HJ; Koh YB; Bang BK
    Am J Nephrol; 1998; 18(5):373-8. PubMed ID: 9730559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mutations in the
    Demin MV; Tikhomirov DS; Biderman BV; Drokov MY; Sudarikov AB; Tupoleva TA; Filatov FP
    Vopr Virusol; 2022 Mar; 67(1):37-47. PubMed ID: 35293187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
    García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
    Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.